HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

BPC 157

amino acid sequence given in first source; a 15-amino acid fragment of a gastric peptide, BPC, with hepatoprotective effects
Also Known As:
BPC 15; BPC-15; BPC-157; booly protection compound 15; L-Valine, glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-L-prolylglycyl-L-lysyl-L-prolyl-L-alanyl-L-alpha-aspartyl-L-alpha-aspartyl-L-alanylglycyl-L-leucyl-
Networked: 59 relevant articles (12 outcomes, 27 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Sikiric, Predrag: 27 articles (01/2015 - 09/2003)
2. Seiwerth, Sven: 26 articles (01/2015 - 09/2003)
3. Radic, Bozo: 20 articles (01/2015 - 11/2006)
4. Brcic, Luka: 19 articles (01/2014 - 11/2006)
5. Sikiric, P: 17 articles (08/2015 - 01/2001)
6. Drmic, Domagoj: 16 articles (01/2015 - 09/2008)
7. Seiwerth, S: 15 articles (08/2015 - 01/2001)
8. Kolenc, Danijela: 13 articles (01/2015 - 01/2009)
9. Sever, Marko: 11 articles (01/2014 - 01/2007)
10. Ilic, Spomenko: 10 articles (01/2014 - 05/2007)

Related Diseases

1. Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
2. Ulcer
04/01/2004 - "Both intramuscular (im) and intragastric (ig) administration of BPC 157 could apparently reduce the ulcer area and accelerate the healing of induced ulcer in different models and the effect of im administered BPC 157 was better than that of ig. "
12/01/1999 - "A clear protection of the gastrointestinal tract and an evident anti-inflammatory effect were shown for a novel stomach pentadecapeptide BPC 157 (i.p./i.g.) in comparison with several reference standards in various ulcer models along with a protection of endothelium and particular interaction with the NO-system. "
04/01/2004 - "The rats treated with higher dosages (400 ng/kg, 800 ng/kg) of BPC 157 (im and ig) showed significantly less lesion (P<0.01 vs excipient or saline control), the inhibition ratio of ulcer formation varied between 45.7% and 65.6%, from all measurements except 400 ng/kg BPC 157 in pylorus ligation induced model (P<0.05), in which the inhibition rate was 54.2%. "
02/25/2010 - "Gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, an anti-ulcer peptide, efficient in inflammatory bowel disease trials (PL 14736), no toxicity reported, improved muscle crush injury. "
09/01/2010 - "Previously, as an effective peptide therapy, stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, an anti-ulcer peptide effective in inflammatory bowel disease therapy (PL 14736)) particularly improved healing of transected tendon and muscle and wound healing effect including the expression of the early growth response 1 (egr-1) gene. "
3. Wounds and Injuries (Trauma)
4. Edema
5. Burns

Related Drugs and Biologics

1. 1-dodecylpyridoxal (PLD)
2. Nitric Oxide (Nitrogen Monoxide)
3. Warfarin (Coumadin)
4. Heparin (Liquaemin)
5. Aspartate Aminotransferases (Aspartate Transaminase)
6. Alanine Transaminase (SGPT)
7. 1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
8. L-Lactate Dehydrogenase (Lactate Dehydrogenase)
9. Ibuprofen (Motrin)
10. Creatine Kinase (Creatine Phosphokinase)

Related Therapies and Procedures

1. Amputation
2. Ligation
3. Gastrectomy
4. Anesthesia
5. Catheters